ESEV
Contract research organization founded in 2014 focused on R&D, testing, and commercialization support for plant-derived and cannabis-related formulations for human and animal use. Provides formulation development, preclinical and early-phase clinical studies, bioavailability and safety testing, regulatory consulting, and business development leveraging partnerships with Israeli medical and laboratory organizations.
Industries
Nr. of Employees
small (1-50)
Services
Development of cannabinoid and co-formulations to enhance local or systemic bioavailability and performance.
Preparation of clinical and preclinical study protocols aligned with client objectives, budgets and timelines.
Execution and management of in vivo animal studies for safety, tolerability and efficacy assessment.
Conduct of early-phase human trials to evaluate safety and initial pharmacology for new formulations.
Comparative bioavailability and pharmacokinetic studies measuring plasma and target-site concentrations following administration.
Integrated laboratory, animal and human studies to demonstrate safety and efficacy of products.
Development of cannabinoid and co-formulations to enhance local or systemic bioavailability and performance.
Preparation of clinical and preclinical study protocols aligned with client objectives, budgets and timelines.
Execution and management of in vivo animal studies for safety, tolerability and efficacy assessment.
Conduct of early-phase human trials to evaluate safety and initial pharmacology for new formulations.
Comparative bioavailability and pharmacokinetic studies measuring plasma and target-site concentrations following administration.
Integrated laboratory, animal and human studies to demonstrate safety and efficacy of products.
Expertise Areas
- Clinical trial management and protocol design
- Formulation development for improved bioavailability
- Preclinical in vivo pharmacology and toxicology
- Bioavailability and pharmacokinetic analysis
Key Technologies
- Formulation technologies for bioavailability enhancement
- In vivo rodent models
- Pharmacokinetic plasma assays
- Target-site (synovial fluid) concentration analysis
News & Updates
Pharmacokinetic and safety study in rats comparing standard and fast-acting cannabinoid gummies; plasma THC concentrations measured up to five hours post-dose.
Formulation development for a women's health product combining multiple active ingredients with a dominant cannabinoid; evaluation of GRAS ingredients and endocannabinoid receptor targeting.
Preclinical animal study evaluating combinations of cannabidiol with deep ocean minerals for rehydration and recovery; reported improved outcomes versus controls.
Palatability and preclinical/clinical study designs for veterinary chew formulations containing cannabidiol and glucosamine, including behavioral and biochemical endpoints.
Comparative bioavailability study of three water-soluble oral cannabidiol formulations in rats with plasma sampling at multiple time points.
Animal studies showing increased glucosamine uptake into synovial fluid when combined with cannabidiol and other ingredients.
Pharmacokinetic and safety study in rats comparing standard and fast-acting cannabinoid gummies; plasma THC concentrations measured up to five hours post-dose.
Formulation development for a women's health product combining multiple active ingredients with a dominant cannabinoid; evaluation of GRAS ingredients and endocannabinoid receptor targeting.
Preclinical animal study evaluating combinations of cannabidiol with deep ocean minerals for rehydration and recovery; reported improved outcomes versus controls.
Palatability and preclinical/clinical study designs for veterinary chew formulations containing cannabidiol and glucosamine, including behavioral and biochemical endpoints.
Comparative bioavailability study of three water-soluble oral cannabidiol formulations in rats with plasma sampling at multiple time points.
Animal studies showing increased glucosamine uptake into synovial fluid when combined with cannabidiol and other ingredients.